% differences compared with placebo or indicated statin are based on differences of individual least square means for LDL-C, HDL-C, non-HDL-C and apoB, and on differences of individual medians or ...

and apolipoprotein B ≤110 mg/dL were randomly assigned to one of four treatment groups: rosuvastatin 10-40 mg, ER niacin 0.5-2 g, rosuvastatin 40 mg plus ER niacin 0.5-1 g, or rosuvastatin 10 mg ...

In clinical practice, a combination of drugs is often used to treat patients with dyslipidemia who are not achieving their treatment goals. Ezetimibe reduces LDL cholesterol levels, and niacin ...